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standard in health technology assessment, quantitative methods are
less frequent but increasingly used for beneﬁt-risk assessment (BRA) at
earlier stages of drug development. A frequent challenge when
implementing metrics for BRA is to weigh the importance of effects
on a chronic condition against the risk of severe events during the
trial. The lifetime component of the QALY model has a counterpart in
the BRA context, namely, the risk of dying during the study. Methods:
A new concept is presented, the hazard of death function that a
subject is willing to accept instead of the baseline hazard to improve
his or her chronic health status, which we have called the quality-of-
life–adjusted hazard of death. Results: It has been proven that if
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lands.tolerated by a subject for a chronic health improvement is inversely
proportional to the mean residual life. Conclusions: This result leads
to a new representation of the linear QALY model in terms of hazard
rate functions and allows utilities obtained by using standard methods
involving trade-offs of life duration to be translated into thresholds of
tolerated mortality risk during a short period of time, thereby avoiding
direct trade-offs using small probabilities of events during the study,
which is known to lead to bias and variability.
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The concept of quality-adjusted life-years (QALY) has been
routinely used to guide health care policymaking since its
inception some 30 years ago. QALYs provide a very intuitive
way of combining the two main components of health, namely,
life duration and quality of life (QOL), into a single index. In its
simplest form, which is linear with respect to time, the QALY
model is formulated as QALY (T,Q) ¼ T  g(Q), where T is the life
duration and g is a utility function over the health states.
More recently, regulatory agencies, pharmaceutical compa-
nies, and other groups have begun to discuss and explore
methods to improve and standardize the beneﬁt-risk assessment
(BRA) performed throughout all drug development phases and
during the assessment of a marketing authorization application.
In this context, three detailed reviews of quantitative methods
with potential use during BRA have been published [1–3]. Some of
the models and metrics proposed for BRA, such as relative value-
adjusted number needed to treat, global beneﬁt risk, and multi-
criteria decision analysis, share the idea of combining risks and
beneﬁts into a single index by incorporating patients’ or decision
makers’ preferences [4–6]. These models do not necessarily
decompose the subject’s outcomes into the two dimensions ofthe QALY model but are often based on a set of clinical trial end
points selected for each evaluation.
Although the Work Package 2 report of the European Medi-
cines Agency Beneﬁt Risk Methodology Project concluded that
regulators still ﬁnd QALY insufﬁciently comprehensive for drug-
related BRA, the existence of aspects common to QALY and other
BRA models that deserve further research was acknowledged [2].
Herein, we concentrate on the inverse relationship between the
life duration component of the QALY model and the risk of death
during a clinical trial and use the hazard function, which is a key
concept in time-to-event models, to establish a line of commu-
nication between the two frameworks.Utilities in the QALY Model
In the QALY model, a chronic health state Q0 is quantiﬁed on a 0
to 1 scale, with 1 representing perfect health and 0 representing
death. Two common ways to elicit the utility of health status Q0
are standard gamble (SG) and time trade-off (TTO).
SG is the most classical method for quantifying preferences in
decision theory. With the SG probability equivalent (PE) method,
decision makers are asked to ﬁx a probability p such that they areociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 2 7 5 – 2 7 9276indifferent between a certain consequence of living the rest of
their lives in health state Q0 and a lottery in which they will live
with a better health state Q1 with a certain probability p or will die
immediately with the opposite probability (1 – p). Although Q1
normally represents perfect health, a more general use that
compares two arbitrary states Q0 and Q1, the latter of which is
preferred to Q0, is assumed throughout this article. Assuming
that the interviewee is a von Neumann–Morgenstern rational
agent, the obtained probability p is taken as the utility of Q0 on
the 0 to 1 scale, where 0 is death and 1 is health state Q1. SG
utilities are believed to be upward biased due to loss aversion and
probability weighting effects [7,8].
The TTO method asks for the duration (T1) that yields indif-
ference between living T0 years in Q0 status and living T1 years in
another health status Q1 that is preferred to Q0. When utility of
life duration is assumed to be linear, the utility of health state Q0
with respect to Q1 is calculated as u ¼ T1/T0. Some authors have
warned of a possible downward bias of TTO utilities, mainly due
to life duration curvature, whereas others have suggested a
possible upward bias caused by loss-aversion and scale-
compatibility effects [7,9]. It has also been hypothesized that
both downward and upward biases might cancel out, thereby
possibly explaining empirical evidence suggesting the greater
accuracy of TTO when it comes to reﬂecting preferences over
other methods such as SG [7–12].Weights for Beneﬁt-Risk Metrics
To compare both frameworks, in this section we deﬁne a simple
weighted-sum multicriteria decision analysis model for BRA over
two clinical trial end points, namely, the chronic health state
achieved at steady state Q and the risk of death during the study
D. If the variable Q has two possible values, Q0 and Q1, preferred
to Q0, the model can be expressed by
Score ¼w PðQ1ÞPðDÞ ð1Þ
where P(Q1) is the probability of achieving health state Q1 and P(D)
is the probability of death during the study. This simple BRA
metric requires the ﬁxing of a weight w that represents the
importance of a swing from the chronic health state Q0 to Q1 with
respect to a swing from Q0 to death during the study period. By
using a PE gamble, decision makers might be asked to ﬁx a
probability p such that they are indifferent between a certain
consequence of a chronic health state Q0 at steady state in the
clinical trial and a lottery in which the patient will achieve health
state Q1 with a certain probability p or will die during that period
of time with the opposite probability (q ¼ 1 – p). If they accept a
probability of death q ¼ 0.03 (3%), then a swing from 0% to 3% in
the percentage of subjects dying during the study will be
concluded to have the same importance as a swing in the chronic
health status from Q0 to Q1, leading to a weight w ¼ 0.03.
One aspect that deserves attention is the fact that the quanti-
ﬁcation of preferences for the decision models proposed for BRA
have often required trade-offs using small probabilities [13–15].
Individuals, however, are not perfect von Neumann–Morgenstern
agents, and PE gambles that handle probabilities close to 0 are
known to provide biased and variable quantiﬁcations [7,8,16–18].
Herein, we propose to avoid trade-offs that use low probabilities of
events during the study and to focus on trade-offs of life duration.
This article proposes a procedure to translate these TTO utilities
into weights that could be useful for BRA metrics.The Hazard Function and the Mean Residual Life
The hazard function h(t), also known as failure rate or hazard
rate, is a key concept in time-to-event statistics that representsthe instantaneous risk of suffering the event of interest at time t
for a subject who has survived to that moment in time. The
hazard rate quantities are not probabilities but range from 0 to
inﬁnite and depend on both the strength of the risk and the time
units used. For example, both a mortality hazard rate of 0.015
deaths per subject-month and 18 deaths per 100 subject-years
represent the same instantaneous risk at a given time t but
expressed in different units. The hazard function h(t) of a random






Another function that deserves special attention here is the
mean residual life (MRL), also called expected remaining lifetime.
The MRL provides the expected value for the lifetime remaining
at any time t, given that the subject is known to have survived to
t. Although two different random variables T and T’ may share
the same expected value E(T) ¼ E(T’), the complete MRL(t)
function over time uniquely deﬁnes the probability distribution







where ST(t) is the survival function, that is, deﬁned as ST(t) ¼ P(T
4 t).
In expected utility, a subject is said to be risk-neutral with
respect to the remaining life duration if he or she is indifferent
over any lotteries with the same expected value. If lotteries over
life duration are formulated in terms of hazard functions, risk
neutrality over life durations is given by a subject being indif-
ferent to any two hazard functions h0 and h1 provided the
expected remaining lifetime is the same.
A risk-neutral 30-year-old subject would be indifferent
between the two lotteries of lifetime durations L0 and L1 asso-
ciated with the two hazard functions of death h0 and h1,
illustrated in Figure 1, because both have the same expected
value (52.3 years) when the subject is 30 years old. The same two
hazard functions can be used to represent not only the lotteries
at an initial time t ¼ 0 but also the subsequent lotteries L0(t) and
L1(t) for subjects who survive to later times. If the same risk-
neutral subject survives to the age of 70 years and is again asked
to choose between these two hazards, he or she will prefer the
lottery represented in Figure 1 by the solid line because this
function provides a higher MRL at this later age.The Quality-of-Life–Adjusted Hazard of Death
In survival analysis, the term baseline hazard is used to represent
the risk of death estimated for a subject or group of similar
subjects over time and, as such, related to our knowledge of their
diseases and demographic characteristics. The baseline hazard
function h0 is associated with a probability distribution of life-
times L0.
A quality-of-life–adjusted hazard of death (QAHD) function is
deﬁned as a hazard function of death, h1(t), that a person is
willing to accept at any time t, instead of his or her baseline
hazard of death h0(t), to improve his or her health status from
any given level Q0 to any other level Q1.
In other words, h1(t) is the QAHD for an improvement from Q0
to Q1 if that person is indifferent between being in health state Q0,
with its baseline lifetime probability distribution L0, for the rest of
his or her life and being in health state Q1, with distribution L1,
where h0(t) and h1(t) are the hazard functions associated with
probability distributions L0 and L1, respectively. We intentionally
restrict the deﬁnition of QAHD to lifetime distributions L1 that
meet the condition whereby if a subject survives to an interim
Fig. 1 – Hazard rate andmean residual life of two random variables. * Weibull distribution with parameters λ = 0.0173 and k = 4;
† Gompertz-Makeham distribution with parameters a = 0.00008677, b = 0.1267 and c = 0.00045.
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in health status Q0 versus Q1 under the two new probability
distributions of remaining lifetime durations obtained from
h0 and h1, respectively, conditioned to survival to time t. This
deﬁnition cannot be applied to compare a reference health state
Q1 considered better than death with another health state Q0
regarded worse than death because such states violate the
mutual utility independence assumption and thus for any hazard
functions h0(t) and h1(t) the subject will always prefer {Q1, h1(t)}
over {Q0, h0(t)}.
If h1(t) is a QAHD for a chronic condition Q0, we deﬁne the
maximally tolerated excess mortality risk function for an
improvement from Q0 to Q1 as the difference between the QAHD
function and the baseline risk and express it as λ(Q0, t). A general
form for the QAHD is then given by h1(Q0, t) ¼ h0(t) þ λ(Q0, t). Below,
two possible behaviors are presented concerning how the toler-
ated excess mortality risk for an improved chronic health con-
dition might change as the subject’s baseline risk varies over time.
In the next section, we will prove that the QALY model represents
a middle ground between these two assumptions. Constant additive trade-off of mortality rate would hold if the
excess mortality risk λ that a person is willing to add to his or
her baseline hazard of death to improve his or her health
status from any given level Q0 to any other level Q1 is constant
over time. Under the constant additive trade-off of mortality
rate assumption, the QAHD function is expressed as h1(Q0, t) ¼
h0(t) þ λQ0. Constant proportional trade-off (CPTO) of mortality rate would
hold if a person is willing to increase his or her baseline
hazard of death multiplicatively from h0(t) to h0(t)  k to
improve his or her health status from any given level Q0 to
any other level Q1. Under the CPTO of mortality rate assump-
tion, the QAHD function is given by h1(Q0, t) ¼ h0(t)  kQ0 and
the tolerated excess mortality risk function can be expressed
as λ(Q0, t) ¼ [h0(t) – 1]  kQ0 .
Because a 90-year-old subject from the general population has
an approximately 300 times higher mortality rate than when
aged 30 years [19], it might be difﬁcult to assume that a person’s
tolerated excess mortality risk for a chronic health state improve-
ment remains constant after this remarkable change in baseline
risk. Moreover, it may also be unrealistic to assume that both
baseline risk and tolerated risk have a strictly proportional
relationship; that is, if the baseline risk is multiplied by 300, the
risk of death tolerated for an improvement in chronic health
status is also multiplied by 300.The QAHD under the QALY Model
The CPTO of life duration assumption is said to hold if the
number of remaining years of life that a person is willing to give
up to improve his or her health status from any given level Q0 to
any other level Q1 is a ﬁxed ratio of the absolute number of
remaining life-years. This assumption is typical of the QALY
model and does not characterize the risk attitude of the subject
but rather how the trade-offs of riskless life durations and QOL
change as the duration used as reference varies. Multiple studies
have checked this assumption empirically and found mixed
results, suggesting not only that this assumption might not
perfectly hold but also that the deviations from this behavior
might not be large [12,20,21].
Theorem
If a subject in a chronic condition Q0 has a baseline hazard rate of
death h0(t) and all three conditions of the linear QALY model
(mutual utility independence, CPTO of remaining life duration,
and risk neutrality over lotteries in life duration) hold, then the
hazard function h1(t) that the subject is willing to accept at any
time t to improve his or her health status from level Q0 to another









where MRL0(t) is the MRL function derived from h0(t), and u is the
utility of Q0 with respect to the reference state Q1 consistent with
the linear QALY model.
Demonstration
Let h0(t) be the baseline death hazard function deﬁned over any t
Z 0 for a subject in health state Q0 and MRL0(t) be the subject’s
mean residual life function associated with this hazard function.
At t ¼ 0, life expectancy is denoted simply as T0. If T and Q are
mutually independent, there should be a lifetime T1 4 0 for
which living T0 years in health state Q0 is indifferent to living T1
years in health state Q1. The utility u of heath state Q0 is deﬁned
as the ratio T1/T0. If risk neutrality over lotteries in life duration
holds, this indifference is maintained if, instead of offering ﬁxed
(riskless) life durations, two lotteries h0(t) and h1(t) are proposed
with life expectancies T0 and T1, respectively. In addition, the
CPTO of remaining lifetime guarantees that if the lottery h1(t) is
chosen to maintain the indifference between h0(t) in health state
Q0 and h1(t) in health state Q1 also at later times t 4 0, then
MRL1(t)/MRL0(t) should equal T1/T0 at any t Z 0. The appendix
F
c




Baseline hazard of death* 0.08 0.61 24.37
QAHD for u ¼ 0.9 * 0.30 1.13 28.14
Absolute difference (QAHD 
baseline)*
0.22 0.52 3.78
Relative difference (QAHD/baseline) 3.98 1.86 1.16
QAHD, quality-of-life–adjusted hazard of death.
* Units are deaths per 100 subject-years.
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jval.2013.11.013) contains the proof that there is only one possible
hazard function h1 consistent with this equivalence, namely, that
given by Equation 4.
The assumptions of the QALY model result in subjects eager to
tolerate higher increases in their mortality rate as their baseline
risk increases (or lower increases if the baseline risk decreases),
although such increases (or decreases) are not proportional to the
change in baseline risk but inversely proportional to the remaining
life expectancy. Because one of the key assumptions of the linear
QALY model is the CPTO of life duration, it is not surprising that
the resulting form of the QAHD under this model resembles the
hazard function of Oakes and Dasu’s proportional MRL model [22].
Corollary
If all three assumptions of the linear QALY model hold and the
hazard function is nondecreasing, then the QAHD has a lower
bound given by h1(Q0t) Z h0 (t)/u, where u is the utility of Q0 with
respect to the reference state Q1. Demonstration is trivial because
h0(t) r 1/MRL(t) at any t.Example: Tolerated Risk in Crohn’s Disease
The solid line of Figure 2 shows the estimated mortality risk
versus age for patients with Crohn’s disease [19,23]. A group of
decision makers can deﬁne a combined metric for BRA in this
indication by using existing evidence suggesting that the mod-
erate symptoms status (Q0) might have a utility of about 0.9 on
the 0 to 1 scale, where 0 means death and 1 relates to the
remission status (Q1) that they want to use as reference [24].
If all three conditions of the linear QALY model hold, we can
conclude that patients with Crohn’s disease would be willing to
tolerate, for an improvement from Q0 to Q1, an excess mortality
rate of 1/0.9 – 1 ¼ 0.11 times the inverse of the MRL, which is
represented in Figure 2 as the difference between the solid line
and the dotted line. Table 1 shows that the resulting excess risk
tolerated by these subjects increases with age when expressed
additively with respect to the baseline risk but decreases when
stated as the ratio of the baseline risk.
The challenge here is that the tolerated risk depends on a
subject’s MRL, which is not the same for all subjects, changes
over time, and may be difﬁcult to estimate [25]. The above
corollary allows the utility of 0.9 to be translated into a general-
izable lower limit of tolerated mortality risk (dashed line), withig. 2 – Baseline and quality-of-life adjusted hazard of death in Cro
hronic health state improvement with utility u = 0.9.the only condition that the population risk of death increases
over time, which is a reasonable assumption in many popula-
tions. We can therefore conclude that, for any subject, a swing in
the QOL attribute from moderate to remission status would be
regarded at least as important as a 1.11-fold increase in the risk
of death.
The lower limit should, however, be used cautiously because
it may be too conservative. It notably underestimates the toler-
ated risk of death for an improvement in their health status for
the younger subjects of Figure 2. It might also be anticonserva-
tive, and thus inappropriate, in indications in which the main
beneﬁt of a new drug is an increase in life expectancy and a
worsened QOL is the price to pay for that beneﬁt.Conclusions
Quantitative models and metrics for BRA often require quantify-
ing the patients’ tolerance to risk for an improvement in their
chronic condition. As such, BRA models need to pay more
attention to the effect, in term of bias and noise, of asking
patients or decision makers to make trade-offs by using small
probabilities of suffering unfavorable events during the study.
Herein, we have proposed an alternative solution comprising
the use of trade-offs of life duration. In this regard, we have
related the well-known concept of QALYs to the hazard rate
function and have introduced a new concept, namely, the hazard
rate of death that a subject is willing to accept to improve his or
her chronic health status, instead of the baseline hazard, which
we have called the QAHD. Furthermore, we have shown that if
usual assumptions of the linear QALY model hold, the excesshn’s disease. * Quality-of-life adjusted hazard of death for a
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or her health status is inversely proportional to the remaining life
expectancy. This result leads to a new representation of the
linear QALY model, for the simple case in which an individual is
in the same state for the remaining years of his or her life, in
terms of hazard rate functions. We have shown how to transform
utilities obtained from trade-offs of life duration into tolerated
excess mortality rates that can be used in BRA models deﬁned
over a short evaluation period, thereby avoiding the need for
direct trade-offs using low probabilities of death during the study.
This procedure assumes CPTO of life duration, an assumption
that might not perfectly hold but still appears more prudent and
supported by previous literature than other assumptions such as
constant or proportional trade-off of mortality rate.
Although we have focused herein on the risk of death during
the study, models for BRA often include other severe but nonfatal
events. In these situations, it may still be useful to initially obtain
a weight for death to be used as a reference and then estimate
weights for other nonfatal severe events, for example, a nonfatal
myocardial infarction, by quantifying the loss of QOL and life
expectancy caused by this event with respect to the total loss
implied by the subject’s death.
One important limitation of this article is its focus on the
most conventional QALY model that assumes the same health
status maintained over the remaining life, risk neutrality, and no
discounting. Further research is recommended to extend this
work and translate other more sophisticated QALY models into
the new proposed formulation in terms of hazard rate functions
and to investigate other potential uses of this representation not
only in the ﬁeld of BRA but also in other areas.
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